Pasithea Therapeutics Corp. (KTTAW) Net Income towards Common Stockholders (2021 - 2026)

Pasithea Therapeutics has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$5.3 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 41.92% year-over-year to -$5.3 million; the TTM figure through Jun 2026 stood at -$21.3 million (down 58.22% YoY), while the FY2025 annual figure was -$20.4 million, down 46.91% from the prior year.
• Net Income towards Common Stockholders came in at -$5.3 million for Q2 2026 at Pasithea Therapeutics, down from -$2.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.9 million in Q1 2022 to a low of -$10.1 million in Q4 2025.
• Average Net Income towards Common Stockholders over 5 years is -$4.2 million, with a median of -$3.7 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders plunged 1454.4% in 2022 and surged 40.09% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$8.5 million in 2022, then surged by 40.09% to -$5.1 million in 2023, then jumped by 37.85% to -$3.2 million in 2024, then plunged by 218.19% to -$10.1 million in 2025, then jumped by 47.84% to -$5.3 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$5.3 million in Q2 2026, -$2.9 million in Q1 2026, and -$10.1 million in Q4 2025.